Analysts Set Expectations for OS Therapies FY2030 Earnings

OS Therapies Incorporated (NYSEAMERICAN:OSTX) – Equities researchers at Brookline Capital Markets issued their FY2030 earnings estimates for OS Therapies in a research note issued to investors on Friday, May 1st. Brookline Capital Markets analyst K. Raja expects that the company will earn $0.42 per share for the year. The consensus estimate for OS Therapies’ current full-year earnings is ($0.52) per share.

OS Therapies (NYSEAMERICAN:OSTX) last announced its earnings results on Tuesday, March 31st. The company reported ($0.41) earnings per share for the quarter.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a report on Thursday, April 30th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, OS Therapies presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.50.

OS Therapies Price Performance

Shares of NYSEAMERICAN:OSTX opened at $1.66 on Tuesday. The company’s fifty day moving average price is $1.45 and its 200-day moving average price is $1.56. The firm has a market capitalization of $65.62 million, a price-to-earnings ratio of -1.68 and a beta of -1.34. OS Therapies has a one year low of $1.15 and a one year high of $2.57.

Hedge Funds Weigh In On OS Therapies

A number of large investors have recently added to or reduced their stakes in OSTX. State Street Corp boosted its position in OS Therapies by 16.3% during the fourth quarter. State Street Corp now owns 58,500 shares of the company’s stock valued at $82,000 after buying an additional 8,200 shares during the period. Susquehanna International Group LLP bought a new position in shares of OS Therapies in the third quarter worth approximately $29,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of OS Therapies in the third quarter worth $40,000. Ground Swell Capital LLC bought a new stake in OS Therapies during the 3rd quarter valued at $40,000. Finally, Bridgeway Capital Management LLC bought a new stake in OS Therapies during the 2nd quarter valued at $47,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.